Make us your home page

Today’s top headlines delivered to you daily.

(View our Privacy Policy)

Drugmakers in a race to develop new anti-cholesterol medicines

NEW YORK — A handful of drugmakers are racing to develop a new class of medicines that they believe could be the biggest weapon against heart disease since statins were introduced in the 1980s.

The contest is taking place largely out of public view, but researchers and industry analysts say excitement is building over the injectable medicines. They work by blocking PCSK9, a protein whose natural function is to preserve levels of "bad" LDL cholesterol in the bloodstream.

Researchers in Paris, Montreal and Dallas, through experiments with thousands of patients that began in 1999, discovered the gene behind PCSK9 and deciphered its function.

Biotechnology company Regeneron and its big pharmaceutical partner Sanofi are now ahead of the pack in developing a drug that goes after PCSK9. A single injection of their medicine, called REGN727, slashed LDL levels by more than 60 percent for a month in an early trial. Results from mid-stage studies are expected later this year.

"The PCSK9 mechanism is perhaps one of the best examples we have in all of medicine of how the study of genetics can identify new targets for developing new therapies," said Dr. Daniel Rader, a noted heart researcher at the University of Pennsylvania.

Although no serious side effects have been seen with REGN727, larger trials are needed to rule out problems such as liver toxicity or raised blood pressure that have wrecked other promising heart drugs, including Pfizer Inc.'s experimental torcetrapib.

Rader, who is a consultant to several of the companies developing PCSK9 inhibitors, said most drugmakers are working on once-a-month injections that would likely be self-administered by patients using very small needles. Some drugs might eventually be administered every two to three months, he said.

Amgen Inc., Merck & Co., Alnylam Pharmaceuticals Inc. and a partnership between Bristol-Myers Squibb Co. and Isis Pharmaceuticals Inc. are in hot pursuit with rival drugs of their own.

The anti-PCSK9 medicines are expected to be used alongside statins, such as Pfizer's Lipitor and AstraZeneca's Crestor, for patients who do not achieve cholesterol-lowering goals with statins alone.

They would also be used on their own for a much smaller group who cannot tolerate statins — oral drugs with global annual sales of $20 billion that inhibit the liver's production of LDL cholesterol.

In the United States, more than 10 million patients could ultimately be candidates for the new family of medicines. Industry analysts say the products could command $1,000 a month or more because of their potential importance to high-risk patients. Statins cost about $130 a month for branded pills like Lipitor.

Drugmakers in a race to develop new anti-cholesterol medicines 08/27/11 [Last modified: Friday, August 26, 2011 8:28pm]
Photo reprints | Article reprints


Join the discussion: Click to view comments, add yours

  1. One of St. Petersburg's newest condo projects is sold out

    Real Estate

    ST. PETERSBURG — Reflecting the continued demand for condos in downtown St. Petersburg, The Salvador, completed earlier this year at 199 Dali Blvd., has sold out. Records show that a 2-bedroom, 2-bath unit sold Friday for $620,000 in an all-cash deal. Two other units — a 3-bedroom, 2-bath penthouse and a …

     Reflecting the continued demand for condos in downtown St. Petersburg, The Salvador, completed earlier this year at 199 Dali Blvd., has sold out. 
[Rendering courtesy of aalliiggnn LLC]
  2. Tedd Webb, co-host of top morning radio show, calling it quits after five decades

    Human Interest

    TAMPA — It's 9 Monday morning and Tedd Webb is exhausted.

    Radio personality Tedd Webb hopes to continue spending an hour each mid-day on the financial show The Opening Bell but he'll be stepping down from the top-rated morning show he co-hosts with Jack Harris. [JAMES BORCHUCK   |   Times]

  3. Pasco OKs higher fee for drainage work

    Local Government

    DADE CITY — Trying to keep neighborhoods drier is going to cost Pasco County property owners some extra dollars.

    Commissioner Mike Wells Jr., who voted against a higher storm-water fee in February, supported the increase this time. "Bottom line: It's needed,'' he said.
  4. Florida Gators announce 2018 football schedule


    The Florida Gators announced their 2018 football schedule Tuesday, including an early SEC game against Kentucky and a matchup against Colorado State, which was part of coach Jim McElwain's buyout from the Rams.

  5. Directors of Haunted Mansion doc talk bringing piece of Disney history to Orlando


    Filmmakers Ryan Grulich and James H. Carter II aren't just casual fans of The Haunted Mansion ride. They're obsessed.

    Publicity still from the Foolish Mortals documentary.